Kairos Pharma, Ltd. (KAPA)

NYSEAMERICAN: KAPA · Real-Time Price · USD

0.8900

-0.0193 (-2.12%)

At close: Dec 5, 2025, 4:00 PM EST

0.8880

-0.0020 (-0.22%)

After-hours: Dec 5, 2025, 8:00 PM EST

Kairos Pharma Employees

As of December 31, 2024, Kairos Pharma had 4 total employees, including 1 full-time and 3 part-time employees.

Employees

4

Change

n/a

Growth

n/a

Revenue / Employee

n/a

Profits / Employee

-$1,265,500

Market Cap

18.53M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	4	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

KAPA News

4 weeks ago - Kairos Pharma Provides Shareholder Update - Business Wire
6 weeks ago - Kairos Pharma Presents on Phase 2 Trial of ENV-105 in Advanced Prostate Cancer at European Society Medical Oncologists (ESMO) Meeting - Business Wire
2 months ago - Kairos Pharma to Present Positive Safety and Efficacy Data from Phase 2 Prostate Cancer Trial at ESMO 2025 - Business Wire
2 months ago - Kairos Pharma Announces Positive Interim Efficacy Analysis of Phase 2 Trial of ENV105 in Advanced Prostate Cancer with Median Progression Free Survival of Over One Year - Business Wire
3 months ago - Kairos Pharma Announces Virtual KOL Event to Provide Perspectives on ENV105 Interim Efficacy Results in Advanced Prostate Cancer - Business Wire
3 months ago - Kairos Pharma Announces Presentation of New Phase 1 Data on ENV105 Combination Therapy in Non-Small Cell Lung Cancer at the World Lung Cancer Conference September 6-9, 2025 - Business Wire
3 months ago - Kairos Pharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference - Business Wire
4 months ago - CEO.CA's Inside the Boardroom: Kairos Pharma CEO on Phase 2 Safety Data, 165% Stock Move & September Efficacy Timeline - Newsfile Corp